In many developing countries and outside hospital settings, the characteristics of endemic Mycobacterium tuberculosis strains resistant to multiple drugs remain unknown. In a community-based referral and therapy program in northern Lima, Peru, beginning in 1996, patients found to be failures on standard regimens were referred for drug-susceptibility testing of their isolates, and those found to be infected with M. tuberculosis isolates resistant to at least rifampin were treated with individualized regimens based on their infecting strains. Isolates from 42 of these patients were subjected to DNA sequencing of the rpoB gene region responsible for rifampin resistance. We determined the frequency of types of mutations in the rpoB gene among these Peruvian isolates.
INTRODUCTION T
HE GLOBAL RESURGENCE OF TUBERCULOSIS (TB) is related not only to rising rates of coinfection with human immunodeficiency virus (HIV) but also to increasingly resistant strains of tuberculosis resulting in spread of primary drug resistance. Multidrug-resistant tuberculosis (MDR-TB) is defined as resistance to at least isoniazid and rifampin, given the highly efficacious nature of these two drugs. For patients infected with MDR-TB, treatment involves a prolonged multidrug regimen, including second-line drugs with higher rates of drug toxicity and lower rates of cure. 9 Cure rates are even worse among HIVcoinfected patients. 7 For both HIV-negative and HIV-positive patients, timely diagnosis of MDR-TB and initiation of appropriate therapy significantly improves treatment outcome. 26 As more countries implement MDR-TB treatment programs, greater is the need for effective methods to identify MDR strains rapidly. Although several rapid phenotypic methods offer promise, genotypic testing based on the identification of mutations conferring resistance to rifampin (RIF) is the most rapid method available to date. Given that 90% of M. tuberculosis isolates resistant to RIF are also resistant to isoniazid, the confirmation of RIF resistance provides an effective screening tool for the identification of MDR strains. 18 Characterization of the rpoB gene has resulted in the identification of mutations conferring resistance to RIF. 24 It is estimated that approximately 96% of mutations responsible for conferring RIF resistance are single amino acid substitutions in the 81-bp core region of the rpoB gene, which encodes the ␤-subunit of RNA polymerase. 13 More than 35 mutations associated with rifampin resistance have been reported in this region. 14 Various methods of detecting mutations in the rpoB gene have been described and reviewed elsewhere. 25 One such method involves DNA sequencing of the rpoB gene region. This method has been shown to be highly concordant with conventional drug susceptibility testing. 11, 15 One site in which an outbreak of MDR-TB has been identified is Lima, Peru. The country of Peru has a population of approximately 26 million and a reported TB incidence of 265 per 100,000 per year in 1999. 5 Yet, in the northernmost districts of Lima, comprising a population of 780,000 in 1997, we estimated a prevalence of active TB cases of approximately 300 per 100,000 with a prevalence of MDR-TB cases of 19.8 per 100,000-at least three times the estimate of MDR-TB preva-lence for the country. 1 We have reported elsewhere the results of drug-susceptibility testing in this series of clinical isolates. 1 The aim of the present study was to examine the frequency of rpoB mutations in isolates from patients with drug-resistant M. tuberculosis in this community. 
MATERIALS AND METHODS

Clinical isolates
Sputum samples were collected from all patients. Acid-fast bacilli stains and cultures were performed either in Lima or at the Massachusetts State Laboratory Institute. 10, 21, 22 Drug susceptibility testing was performed at the Massachusetts State Laboratory Institute using the conventional direct proportion method or BACTEC method (Becton Dickinson, Sparks, MD). For the proportion method, 22 the following concentrations were used: 0.2 g/ml, 1.0 g/ml, and 5.0 g/ml isoniazid (INH), 1.0 g/ml RIF, 5.0 g/ml ethambutol (EMB), 2.0 g/ml and 10.0 g/ml streptomycin (SM), 5.0 g/ml kanamycin (KM), 10.0 g/ml capreomycin (CM), 30.0 g/ml cycloserine (CS), 5.0 g/ml ethionamide (ETH), and 2.0 g/ml ciprofloxacin (CPX). For clinically advanced patients, BACTEC was requested by the evaluating specialist to minimize turn-around time for resistance pattern results. BACTEC method was employed to test for susceptibility to INH (0.2 and 1.0 g/ml), RIF (1.0 g/ml), EMB (5.0 g/ml), and SM (2.0 g/ml). 8, 22 For all isolates, susceptibility to pyrazinamide (PZA) was determined by the BACTEC method, using 100 g/ml. 10 In addition, specialists could request additional drug susceptibility testing to rifabutin according to clinical discretion. These isolates were sent to National Jewish Research and Medical Center in Denver, Colorado, where the isolates were tested on 7H9 agar plates for susceptibility to rifabutin (0.12, 0.5, and 2.0 g/ml).
DNA sequencing
To make PCR products for sequencing of rpoB variable region responsible for rifampin resistance, two primers were used: 5Ј-TCGCCGCGATCAAGGAGT-3Ј and 5Ј-TGCACGTCGCG GACCTCCA-3Ј. 23 Mutations in the 69-bp core region of the rpoB gene were analyzed by commercially available DNA sequencing (ABI Prism, Version 3.0 Model ABI50, ABI), using a method described elsewhere. 12 
DNA fingerprinting
DNA fingerprinting was performed according to standard methods 4, 28 with minor modifications, using IS6110 as a probe 27 and a 1-kb ladder (Invitrogen) as a molecular-weight marker. Cluster analysis of digitized images was performed using BioNumerics software, version 2.00 (Applied Math, London, England, 1998). Dendrogram type was based on unweighted pair group method with arithmetic averages (UP-GMA) and Jacquard similarity coefficient (position tolerance 2.5%, optimization 1%). An IS6110-clustered strain was defined as a strain whose IS6110 RFLP pattern matched 100% according to Bionumerics matrix analysis.
Statistical analysis
Data were stored and analyzed in Excel (Microsoft, 1998) as well as Bionumeric software version 2.00 (Applied Math, London, England, 1998).
RESULTS
All strains were confirmed to be resistant to RIF by conventional and/or BACTEC drug susceptibility testing. Strains were resistant, on average, to 4.7 drugs. In addition, among the nine isolates tested for resistance to rifabutin, all but one were also resistant to rifabutin. All isolates were confirmed by DNA sequencing to have mutations previously described to confer rifampin resistance. Among the 5 patients for whom two samples were analyzed, mutations were identical for both samples. Sequencing revealed that the most common rpoB mutations were found to exist at Ser531 (68.1.%), followed by His526 mutations (23.4%), as shown in Table 1 . In addition, mutations were observed at Asp516 in four samples (8.5%), and at Leu533 in one sample (2.1%). RFLP analysis was performed and IS6110-defined clustering was identified in 33 of the 46 isolates tested, also summarized in Table 1 . Eleven clusters containing between two and nine isolates were identified. The rpoB mutation identified was shared within each of the five clusters identified, with three exceptions. Isolate 97-18879 belonged to cluster E, but unlike the other isolates within this cluster, was identified to have an rpoB mutation other than Ser531. Also, the two isolates, 97-20993 and 97-20980, of cluster J possessed different rpoB mutations.
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Within this cohort, we identified three household clusters comprised of 12 individuals with MDR-TB. All three clusters demonstrated genotypic confirmation of shared infecting strains, both by RFLP and rpoB mutation analysis (see Table  2 ). Interestingly, variation in resistance patterns was observed within these household clusters, likely reflecting divergent acquisition of further resistance once infected by RIF-resistant strains and subjected to subsequent ineffective treatment regimens.
DISCUSSION
Molecular methods have demonstrated utility in the characterization of drug-resistant tuberculosis. Our study, conducted in a setting with a high prevalence of TB, confirmed the utility of DNA sequencing of rpoB gene mutations in identifying MDR strains. In this cohort-all with RIF-resistant strainsrpoB mutations responsible for RIF-resistant phenotypes were successfully identified in all of the isolates tested. Changes in codon Ser531 and His526 have been reported to account for more than 70% of the mutations with RIF resistance. 2, 19 A greater proportion (91%) was seen in this series of clinical isolates. Escalante also reported a predominance of these two mutations among Peruvian isolates of M. tuberculosis. 6 In addition, he observed mutations in Asp516 and Leu533, both of which are identified in our cohort.
Mutations in the codons Asp516 and Ser522 may predict susceptibility to rifabutin among rifampin-resistant strains. 20, 30 On the other hand, mutations affecting 531 or 526 are reportedly associated with high-level rifampin resistance (MIC Ͼ 64 g/ml) and cross-resistance to all rifamycins. 17 In our cohort, however, one isolate possessed a mutation at 526 but demonstrated a phenotype of rifabutin susceptibility.
Portugal et al. suggest the utility of rpoB analysis as a means of identifying subclusters among RFLP clusters. 16 Distinct mutations in the rpoB gene were identified in three subclusters that corresponded to outbreaks, which occurred in separate hospitals. 16 Chaves et al. also describe how subclusters of common rpoB mutations among RFLP-defined clusters tended to be more likely linked epidemiologically. 3 In our cohort, discrepancies between RFLP clustering and rpoB mutations did not correspond to epidemiologic patterns of subclustering. Of note, group E was the only cluster that possessed fewer than six copies of the IS6110 sequence (containing only three), making the interpretation of potential epidemiological clustering suspect. 29 Among individuals who had obvious epidemiological ties as household contacts, both RFLP and rpoB mutations were shared among clusters.
Our interpretation of these results is that the role of rpoB mutations in molecular epidemiology is still unclear. Higher rates of certain mutations, such as Ser531, may not only be related to epidemiological clustering, but also to other factors such as mutation rates and virulence that could influence the incidence of rpoB mutations in a community.
There are several limitations to our data. First, we did not include any strains that demonstrated a RIF-susceptible phenotype. To determine the clinical utility of this method, it would be useful to demonstrate both sensitivity and specificity. However, for early triage, sensitivity may be most important, because the greatest danger of inappropriate therapy is treatment failure and death among MDR-TB cases that are not identified in a timely manner. Second, DNA sequencing was performed here on culture isolates and not directly on sputum samples. Therefore, the performance of the method, if applied directly to clinical specimens, may not be as high. Further exploration applying this assay directly on sputum samples would be helpful to determine if direct testing would be a clinically useful tool.
Nonetheless, this small study demonstrates the potential utility of DNA sequencing of the rpoB gene region to characterize the clinical features of these individuals referred for treatment failure in Lima, Peru. In all samples, a mutation was identified that correlated with rifampin-resistance as demonstrated by conventional or BACTEC methods of drug susceptibility testing. We conclude that analysis of rpoB mutations in clinical isolates of suspected MDR-TB may be an effective tool for confirming MDR strains. While the rpoB mutations correlate with epidemiologic clustering among households, further investigation is required to determine the utility of rpoB mutations in molecular epidemiology.
